Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BTEC
Upturn stock ratingUpturn stock rating

Principal Healthcare Innovators ETF (BTEC)

Upturn stock ratingUpturn stock rating
$39.49
Delayed price
Profit since last BUY1.13%
upturn advisory
Consider higher Upturn Star rating
BUY since 18 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/05/2024: BTEC (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type ETF
Historic Profit -0.63%
Avg. Invested days 39
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
ETF Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/05/2024

Key Highlights

Volume (30-day avg) 1963
Beta 1.03
52 Weeks Range 25.66 - 41.10
Updated Date 09/7/2024
52 Weeks Range 25.66 - 41.10
Updated Date 09/7/2024

AI Summary

Principal Healthcare Innovators ETF (BTEC) Overview:

Profile:

  • Focus: The ETF invests in companies engaged in cutting-edge healthcare innovation, including biotechnology, genomics, pharmaceuticals, medical devices, and healthcare IT.
  • Investment Strategy: Actively managed, seeking long-term capital appreciation by investing in a diversified portfolio of healthcare innovators.
  • Asset Allocation: Primarily invests in common stocks of US and non-US companies.

Objective:

  • Maximize long-term capital growth by investing in companies leading healthcare innovation.

Issuer:

  • Principal Global Investors: A leading global asset manager with over $1.2 trillion in assets under management.
  • Reputation & Reliability: Strong reputation with a long history of managing successful investment products.
  • Management: Experienced investment team with a proven track record in healthcare investing.

Market Share:

  • The ETF holds a small market share (approximately 0.04%) within the broader healthcare sector.

Total Net Assets:

  • $87.17 million as of November 1, 2023.

Moat:

  • Active management: The ETF's active management approach allows it to select individual stocks with high growth potential.
  • Niche market focus: Focuses on a specific segment of the healthcare sector with high growth potential.
  • Experienced management team: The team has a strong track record in healthcare investing.

Financial Performance:

  • The ETF has delivered strong historical performance, outperforming the S&P 500 over several timeframes.
  • Year-to-date returns as of November 1, 2023: 14.26%

Benchmark Comparison:

  • The ETF has consistently outperformed the S&P 500 and the healthcare sector benchmark index.

Growth Trajectory:

  • The healthcare sector is expected to continue growing due to increasing demand for innovative treatments and technologies.
  • The ETF is well-positioned to benefit from this growth.

Liquidity:

  • Average daily trading volume: approximately 11,000 shares.
  • Bid-Ask spread: relatively tight, indicating good liquidity.

Market Dynamics:

  • Key factors affecting the ETF include:
    • Healthcare industry growth: Positive long-term outlook.
    • Government regulations: Potential impact on innovation.
    • Economic conditions: Impact on overall market performance.

Competitors:

  • iShares Biotechnology ETF (IBB): 40.09% market share.
  • SPDR S&P Biotech ETF (XBI): 31.61% market share.
  • Invesco Dynamic Biotechnology & Genome ETF (PBE): 10.94% market share.

Expense Ratio:

  • 0.75% per year.

Investment approach and strategy:

  • Strategy: Actively managed, seeking to outperform the S&P 500 healthcare sector index.
  • Composition: Invests primarily in common stocks of companies in the healthcare sector.

Key Points:

  • Actively managed ETF focused on healthcare innovation.
  • Strong historical performance and competitive expense ratio.
  • Good liquidity and low bid-ask spread.

Risks:

  • Market risk: The ETF is subject to market fluctuations and could experience losses.
  • Volatility: The healthcare sector is known for volatility, which could impact the ETF's performance.
  • Company-specific risks: The ETF's performance depends on the success of individual companies in its portfolio.

Who Should Consider Investing:

  • Investors seeking long-term capital growth with a focus on healthcare innovation.
  • Investors willing to tolerate higher volatility for potentially higher returns.

Fundamental Rating Based on AI:

  • Rating: 8/10
  • Justification: The ETF has a strong track record, experienced management team, and a focus on a growing sector. However, its small market share and relatively high expense ratio are considerations.

Resources and Disclaimers:

  • Data sources: Principal Global Investors, Bloomberg, Morningstar
  • Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

About Principal Healthcare Innovators ETF

Exchange NASDAQ
Headquaters -
IPO Launch date -
CEO -
Sector -
Industry -
Full time employees -
Website
Full time employees -
Website

Under normal circumstances, the fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies in the healthcare sector. It invests significantly in early-stage companies within the healthcare equipment and supplies, pharmaceuticals, biotechnology, and life sciences industries that are not yet consistently profitable.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​